ANTIBIOTICS INCREASE RISK OF HEARING LOSS IN PATIENTS WITH DEADLY BACTERIAL INFECTIONS
Seeking to stem the
tide of permanent hearing loss from the use of life-saving antibiotics,
researchers at Oregon Health & Science University have found that patients
stricken with dangerous bacterial infections are at greater risk of hearing
loss than previously recognized. Inflammation from the bacterial infections
substantially increased susceptibility to hearing impairment by increasing the
uptake of aminoglycoside antibiotics into the inner ear, the researchers
report. Their findings are published in online in the journal Science
Translational Medicine
Currently, it's accepted that the price that some patients
have to pay for surviving a life-threatening bacterial infection is the loss of
their ability to hear. We must swiftly bring to clinics everywhere effective
alternatives for treating life-threatening infections that do not sacrifice
patients' ability to hear," said Peter S. Steyger, Ph.D., professor of
otolaryngology, head and neck surgery, Oregon Hearing Research Center, Oregon
Health & Science University School of Medicine. "Most instances in
which patients are treated with aminoglycosides involve infants with
life-threatening infections. The costs of this incalculable loss are borne by
patients and society. When infants lose their hearing, they begin a long and
arduous process to learn to listen and speak. This can interfere with their
educational trajectory and psychosocial development, all of which can have a
dramatic impact on their future employability, income and quality of
life."
Aminoglycosides, antimicrobials that are indispensable to
treating life-threatening bacterial infections, are toxic to the ear. Relied on
by physicians to treat meningitis, bacteremia and respiratory infections in
cystic fibrosis, aminoglycosides kill the sensory cells in the inner ear that
detect sound and motion.
Infants in neonatal intensive care units, or NICUs, are at
particular risk. Each year, approximately 80 percent of 600,000 admissions into
NICUs in the United States receive aminoglycosides. The rate of hearing loss in
NICU graduates is 2 to 4 percent compared with 0.1 to 0.3 percent of full-term
births from congenital causes of hearing loss.
When Steyger and colleagues gave healthy mice a low amount
of aminoglycoside, the rodents experienced a small degree of hearing loss. If
the mice had an inflammation that is typical of the infections treated with
aminoglycosides in humans, the mice experienced a vastly greater degree of
hearing loss.
The study lays the groundwork for improving the standard of care
guidelines for patients receiving aminoglycosides. To shield patients' hearing,
the researchers called for the development of more targeted aminoglycosides and
urged clinicians to choose more targeted, non-ototoxic antibiotics or
anti-infective drugs to treat patients stricken with severe infections.
Due to their widespread availability and low cost,
aminoglycosides are used frequently worldwide. Clinical use of aminoglycosides
is limited due to the known risk of acute kidney poisoning and permanent hearing
loss, yet are crucial life-savers in cases with potentially fatal infections.
Comments
Post a Comment